Browse
related articles
Hikma acquires Egyptian Pharmaceuticals for $22.2m
- Egypt: Thursday, January 10 - 2013 at 01:51
UK-headquartered Hikma Pharmaceuticals has agreed to buy Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) for around $22.2m in cash to boost its position in the Egyptian market, Bloomberg has reported. The acquisition of EPCI will add a portfolio of 35 products in 46 dosages and strengths, including three cephalosporin anti- infection brands for the Egyptian market, Hikma said. "Since we entered the Egyptian market in 2007, we have been rapidly growing our presence," said the CEO of Hikma, Said Darwazah said. "This acquisition will further accelerate that growth."
Related Content
Article Options
Disclaimer »
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AMEinfo.com Web site does not constitute advice or a recommendation by AME Info FZ LLC / 4C and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AMEinfo.com Web site.
AME Info FZ LLC / 4C can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AMEinfo.com Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / 4C.
In no event shall AME Info FZ LLC / 4C be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AMEinfo.com Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
